Phillips-Medisize, a Molex company, announces the expansion of a significant medical customer for the Molex Little Rock facility. The long-time customer is a leader in consumable diagnostics cancer testing, with its take-home diagnostic kit for cancer detection.
This is an exciting expansion for both the customer and Phillips-Medisize as it will double production, as the device is currently being produced in the Phillips-Medisize New Richmond facility. A second set of molding and dedicated automation machines to package and assemble the device will now be needed for the expanded production footprint in Little Rock.
Phillips-Medisize will mold, assemble with high speed automation, package and label the patient-ready device in the newly registered FDA facility, with production expected to begin in Q2 2018. This product will also include reagent handling and require unique device identification (UDI). Phillips-Medisize will utilize the number of the highly trained and qualified staff that already exists in the Little Rock operation.
The Little Rock facility establishes a new manufacturing site for Phillips-Medisize’s medical business with capabilities for filling, drug handling, electronics and connected devices. This investment aims to combine the innovative solutions and knowledge of Molex’s existing high volume automated electronics production operations with Phillips-Medisize’s proven platform of drug delivery and medical device expertise.
Matt Jennings, CEO and President of Phillips-Medisize comments, “We are looking forward to expanding production with our customer and partnering with the Molex Little Rock team on this program. The team provides decades of experience in molding and assembly operations, cutting edge automation and quality control technology, as well as instant access to a team of highly talented and knowledgeable employees. We believe that Little Rock is the right location for our customer and will support both of our ambitious growth plans.”
